As we move forward with the next generation of PDAC trials, it will be important to move away from generic pancreatic cancer trials and move towards trials that focus on known actionable subtypes, a list that is rapidly expanding and includes BRCA/PALB2 mutations29,30, mismatch repair deficiency31 (MMRd), NRTK fusions32 and NRG1 fusions15. Here, NRG1 is linked to pancreatic neoplasm.